These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37866163)

  • 21. FTO, m
    Mauer J; Jaffrey SR
    FEBS Lett; 2018 Jun; 592(12):2012-2022. PubMed ID: 29754392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. m
    Huff S; Tiwari SK; Gonzalez GM; Wang Y; Rana TM
    ACS Chem Biol; 2021 Feb; 16(2):324-333. PubMed ID: 33412003
    [No Abstract]   [Full Text] [Related]  

  • 23. SIRT1 Regulates N
    Liu X; Liu J; Xiao W; Zeng Q; Bo H; Zhu Y; Gong L; He D; Xing X; Li R; Zhou M; Xiong W; Zhou Y; Zhou J; Li X; Guo F; Xu C; Chen X; Wang X; Wang F; Wang Q; Cao K
    Hepatology; 2020 Dec; 72(6):2029-2050. PubMed ID: 32154934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FTO reduces mitochondria and promotes hepatic fat accumulation through RNA demethylation.
    Kang H; Zhang Z; Yu L; Li Y; Liang M; Zhou L
    J Cell Biochem; 2018 Jul; 119(7):5676-5685. PubMed ID: 29384213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. m
    Takemoto S; Nakano M; Fukami T; Nakajima M
    Biochem Pharmacol; 2021 Nov; 193():114766. PubMed ID: 34536357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural insights into FTO's catalytic mechanism for the demethylation of multiple RNA substrates.
    Zhang X; Wei LH; Wang Y; Xiao Y; Liu J; Zhang W; Yan N; Amu G; Tang X; Zhang L; Jia G
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2919-2924. PubMed ID: 30718435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational Design and Optimization of m
    Huff S; Kummetha IR; Zhang L; Wang L; Bray W; Yin J; Kelley V; Wang Y; Rana TM
    J Med Chem; 2022 Aug; 65(16):10920-10937. PubMed ID: 35939803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FTO: An Emerging Molecular Player in Neuropsychiatric Diseases.
    Annapoorna PK; Iyer H; Parnaik T; Narasimhan H; Bhattacharya A; Kumar A
    Neuroscience; 2019 Oct; 418():15-24. PubMed ID: 31442565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagy of the m
    Cui YH; Yang S; Wei J; Shea CR; Zhong W; Wang F; Shah P; Kibriya MG; Cui X; Ahsan H; He C; He YY
    Nat Commun; 2021 Apr; 12(1):2183. PubMed ID: 33846348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m
    Tan Z; Shi S; Xu J; Liu X; Lei Y; Zhang B; Hua J; Meng Q; Wang W; Yu X; Liang C
    Oncogene; 2022 May; 41(20):2860-2872. PubMed ID: 35422475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
    Wang J; Fu Q; Yang J; Liu JL; Hou SM; Huang X; Cao JS; Liu TL; Wang KZ
    Aging (Albany NY); 2021 Sep; 13(17):21134-21141. PubMed ID: 34496349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemical Inhibitors Targeting the Oncogenic m
    Huang Y; Xia W; Dong Z; Yang CG
    Acc Chem Res; 2023 Nov; 56(21):3010-3022. PubMed ID: 37889223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression.
    Shan HJ; Gu WX; Duan G; Chen HL
    Bioengineered; 2022 Apr; 13(4):8038-8050. PubMed ID: 35311620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.
    Yi W; Yu Y; Li Y; Yang J; Gao S; Xu L
    Bioengineered; 2021 Dec; 12(1):5323-5333. PubMed ID: 34499008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
    Wang F; Hu Y; Wang H; Hu P; Xiong H; Zeng Z; Han S; Wang D; Wang J; Zhao Y; Huang Y; Zhuo W; Lv G; Zhao G
    J Exp Clin Cancer Res; 2023 Oct; 42(1):267. PubMed ID: 37840133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dynamic epitranscriptome: N6-methyladenosine and gene expression control.
    Meyer KD; Jaffrey SR
    Nat Rev Mol Cell Biol; 2014 May; 15(5):313-26. PubMed ID: 24713629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m
    Xu A; Zhang J; Zuo L; Yan H; Chen L; Zhao F; Fan F; Xu J; Zhang B; Zhang Y; Yin X; Cheng Q; Gao S; Deng J; Mei H; Huang Z; Sun C; Hu Y
    Mol Ther; 2022 Mar; 30(3):1104-1118. PubMed ID: 34915192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3'-end processing.
    Bartosovic M; Molares HC; Gregorova P; Hrossova D; Kudla G; Vanacova S
    Nucleic Acids Res; 2017 Nov; 45(19):11356-11370. PubMed ID: 28977517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FTO-Dependent N
    Mathiyalagan P; Adamiak M; Mayourian J; Sassi Y; Liang Y; Agarwal N; Jha D; Zhang S; Kohlbrenner E; Chepurko E; Chen J; Trivieri MG; Singh R; Bouchareb R; Fish K; Ishikawa K; Lebeche D; Hajjar RJ; Sahoo S
    Circulation; 2019 Jan; 139(4):518-532. PubMed ID: 29997116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FTO mediates LINE1 m
    Wei J; Yu X; Yang L; Liu X; Gao B; Huang B; Dou X; Liu J; Zou Z; Cui XL; Zhang LS; Zhao X; Liu Q; He PC; Sepich-Poore C; Zhong N; Liu W; Li Y; Kou X; Zhao Y; Wu Y; Cheng X; Chen C; An Y; Dong X; Wang H; Shu Q; Hao Z; Duan T; He YY; Li X; Gao S; Gao Y; He C
    Science; 2022 May; 376(6596):968-973. PubMed ID: 35511947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.